Pancreatic ductal carcinoma is the most common tumor that affects this gland. Its recovery rates are minimal, not only due to difficulties of an early diagnosis, but also because of the absence of a specific pharmacological treatment. New hopes are coming from a study published on Scientific Reports by the Nanotechnology Institute of CNR, unit of Rende, in collaboration with a team of French and Spanish researchers. A molecule long used to cure anxiety states has been found useful to interfere with the activity of a protein with disordered structure, involved in the development processes of pancreatic tumors.
